ProJenX
Signal active
Organization
Contact Information
Overview
ProJenX is a biopharmaceutical company that develops novel small molecule therapeutics that target motor neuron degenerative pathways. The company was founded in 2021 and is headquartered in Nissequogue, New York.
About
Industries
Biotechnology, Health Care, Biopharma, Therapeutics
Founded
2021
Employees
1-10
Headquarters locations
New York, United States, North America
Social
N/A
Profile Resume
ProJenX headquartered in New York, United States, North America, operates in the Biotechnology, Health Care, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $1.0B in funding across 48 round(s). With a team of 1-10 employees, ProJenX is actively contributing to advancements in Biotechnology. Their latest funding round, Grant - ProJenX, raised $1.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
1
Lead Investors
0
Total Funding Amount
$21.1M
Details
2
ProJenX has raised a total of $21.1M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2023 | Early Stage Venture | 15.0M | ||
| 2022 | Seed | 5.1M |
Investors
ProJenX is funded by 8 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| ProJenX | - | FUNDING ROUND - ProJenX | 5.1M |
| Medical Excellence Capital | - | FUNDING ROUND - Medical Excellence Capital | 5.1M |
| ProJenX | - | FUNDING ROUND - ProJenX | 1.0M |
| The ALS Association | - | FUNDING ROUND - The ALS Association | 1.0M |
Recent Activity
There is no recent news or activity for this profile.